Metabolic Effects of Antidepressants: Results of a Randomized Study's Interim Analysis.
body mass index (bmi )
depressive disorder
egfr creatinine
fasting blood glucose (fbg)
hamilton depression rating scale
serotonin dysfunction
serum triglycerides
total cholesterol levels
vilazodone
vortioxetine
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
accepted:
27
07
2023
medline:
29
8
2023
pubmed:
29
8
2023
entrez:
29
8
2023
Statut:
epublish
Résumé
Individuals with major depressive disorder exhibit a dysregulated metabolic profile. There are few studies on how vilazodone, escitalopram, and vortioxetine alter metabolic parameters. Our study aimed to determine the change in plasma glucose, HbA An ongoing randomized, open-label, three-arm study's interim analysis is portrayed here. The participants were assessed at baseline, 4, 8, and 12 weeks after receiving oral tablets of either vilazodone (20-40mg/d), escitalopram (10-20mg/d), or vortioxetine (5-20mg/d). This study is CTRI-registered (2022/07/043808). Of 71 recruited participants, 49 (69%) completed the 12-week visit. The median Hamilton Depression Rating Scale (HDRS) scores of the participants in vilazodone, escitalopram, and vortioxetine groups were 30.0, 29.5, and 29.0 at baseline (p=0.76) and 19.5, 19.5, and 18.0 (p=0.18) at 12 weeks, respectively. The median fasting blood sugar (FBS) values were 98.5, 105.5, and 98.0 at baseline (p=0.07) and 94.0, 99.5, and 96.0 (p=0.19) at 12 weeks, for vilazodone, escitalopram, and vortioxetine groups, respectively. The post hoc analysis did not yield statistically significant differences regarding any parameters. According to this interim study, the HDRS scores declined after 12 weeks of therapy. The subjects' metabolic parameters did not significantly change. It is essential to perform further investigation regarding these impacts.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Individuals with major depressive disorder exhibit a dysregulated metabolic profile. There are few studies on how vilazodone, escitalopram, and vortioxetine alter metabolic parameters. Our study aimed to determine the change in plasma glucose, HbA
METHODS
METHODS
An ongoing randomized, open-label, three-arm study's interim analysis is portrayed here. The participants were assessed at baseline, 4, 8, and 12 weeks after receiving oral tablets of either vilazodone (20-40mg/d), escitalopram (10-20mg/d), or vortioxetine (5-20mg/d). This study is CTRI-registered (2022/07/043808).
RESULTS
RESULTS
Of 71 recruited participants, 49 (69%) completed the 12-week visit. The median Hamilton Depression Rating Scale (HDRS) scores of the participants in vilazodone, escitalopram, and vortioxetine groups were 30.0, 29.5, and 29.0 at baseline (p=0.76) and 19.5, 19.5, and 18.0 (p=0.18) at 12 weeks, respectively. The median fasting blood sugar (FBS) values were 98.5, 105.5, and 98.0 at baseline (p=0.07) and 94.0, 99.5, and 96.0 (p=0.19) at 12 weeks, for vilazodone, escitalopram, and vortioxetine groups, respectively. The post hoc analysis did not yield statistically significant differences regarding any parameters.
CONCLUSION
CONCLUSIONS
According to this interim study, the HDRS scores declined after 12 weeks of therapy. The subjects' metabolic parameters did not significantly change. It is essential to perform further investigation regarding these impacts.
Identifiants
pubmed: 37641760
doi: 10.7759/cureus.42585
pmc: PMC10460471
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e42585Informations de copyright
Copyright © 2023, Santi et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Int J Appl Basic Med Res. 2018 Apr-Jun;8(2):67-70
pubmed: 29744316
Expert Opin Pharmacother. 2016;17(3):421-31
pubmed: 26679430
Expert Opin Drug Metab Toxicol. 2014 Jan;10(1):121-8
pubmed: 24289655
Cureus. 2023 Apr 20;15(4):e37858
pubmed: 37213947
Lancet. 2019 Jun 15;393(10189):e42-e43
pubmed: 30482607
Curr Med Res Opin. 2006 Jul;22(7):1331-41
pubmed: 16834832
J Clin Psychopharmacol. 2004 Oct;24(5):527-31
pubmed: 15349009
Cureus. 2023 Jun 5;15(6):e39997
pubmed: 37415997
Expert Opin Drug Saf. 2006 Jan;5(1):157-68
pubmed: 16370964
CNS Drugs. 2010 Sep;24(9):741-53
pubmed: 20806987
Pharmacoepidemiol Drug Saf. 2017 Jul;26(7):792-801
pubmed: 28397412
Eur Psychiatry. 2009 Sep;24(6):412-24
pubmed: 19682863
Curr Opin Psychiatry. 2013 Jan;26(1):60-5
pubmed: 23187087
Expert Opin Drug Saf. 2022 May;21(5):673-690
pubmed: 34964415
J Affect Disord. 2022 Aug 15;311:588-594
pubmed: 35597471
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Ann Transl Med. 2019 Nov;7(22):656
pubmed: 31930057